MUMBAI, Sept 1 (Reuters) - India's Cipla Ltd has launched an anti-asthma inhaler in Germany and Sweden that is a generic version of GlaxoSmithKline Plc 's Advair, a move that will further dent sales of the British firm's top-selling product.
index as well as the healthcare sector. However, GlaxoSmithKline (NYSE: GSK ) has been suffering due to some issues in China and ..... again due to recent FDA drug approvals. Moreover, GSK 's deal with Novartis (NYSE: NVS ) has improved
largest publicly traded drug manufacturer in the world, behind giants such as AstraZeneca (NYSE: AZN ), GlaxoSmithKline (NYSE: GSK ), and Pfizer (NYSE: PFE ). Humira Is AbbVie's Biggest Winner AbbVie generated 67% of its 2nd-quarter
market cap) than many familiar pharma names including Sanofi, Lilly, AbbVie, Bayer AG, Bristol-Myers-Squibb, GlaxoSmithKline , AstraZeneca, Novo Nordisk, and Amgen. Gilead is rapidly approaching the market cap of the two largest US pure
Ebola Vaccine in Preclinicals; BioCryst Pharmaceuticals (NASDAQ: BCRX ): BCX4430 in Preclinicals; GlaxoSmithKline (NYSE: GSK ): Ebola Vaccine in Preclinicals; Nanoviricides (NYSEMKT: NNVC ): NV-INF-1 in Preclinicals; Inovio
LONDON, Aug 28 (Reuters) - An experimental Ebola vaccine from GlaxoSmithKline is being fast-tracked into human studies and the company plans to build up a stockpile of up to 10,000 doses for emergency deployment, if results are good.
announcement by U.S. health officials today will state that a human study for the Ebola vaccine made by GlaxoSmithKline (NYSE: GSK ) will begin within a couple of weeks instead of later this year as the company originally estimated. Glaxo
27 (Reuters) - U.S. health officials will announce on Thursday that a human study of an Ebola vaccine made by GlaxoSmithKline will begin within a couple of weeks and not later this year as the company estimated originally, according to people
treatment for the deadly ebola virus. Rumors suggest interested parties could include Shire (NASDAQ: SHPG ) and GlaxoSmithKline (NYSE: GSK ); the report suggests the recent premium paid for InterMune could put a valuation of at least $40/share
diabetes care market. With the share price up more than 20% year-to-date, Novo Nordisk has now surpassed GlaxoSmithKline (NYSE: GSK ) in market capitalization. The short story about earnings Over the past ten years, Novo Nordisk's annualized